Erlichman C - Search Results

1

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.

Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. Adjei AA, et al. Among authors: erlichman c. Invest New Drugs. 2002 Aug;20(3):297-304. doi: 10.1023/a:1016237426846. Invest New Drugs. 2002. PMID: 12201492 Clinical Trial.

2

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

O'Connell MJ, Kahn MJ, Erlichman C, Goldberg RM, Shepherd LE. O'Connell MJ, et al. Among authors: erlichman c. J Clin Oncol. 1996 Oct;14(10):2887. J Clin Oncol. 1996. PMID: 8874353 No abstract available.

3

Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.

Goldberg RM, Erlichman C. Goldberg RM, et al. Among authors: erlichman c. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):59-63. Oncology (Williston Park). 1998. PMID: 9726093 Review.

4

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM. Alberts SR, et al. Among authors: erlichman c. Clin Cancer Res. 1998 Sep;4(9):2111-7. Clin Cancer Res. 1998. PMID: 9748127 Clinical Trial.

5

Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.

Mullany S, Svingen PA, Kaufmann SH, Erlichman C. Mullany S, et al. Among authors: erlichman c. Cancer Chemother Pharmacol. 1998;42(5):391-9. doi: 10.1007/s002800050835. Cancer Chemother Pharmacol. 1998. PMID: 9771954

6

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Lawrence JB, et al. Among authors: erlichman c. Clin Cancer Res. 1997 Oct;3(10):1713-20. Clin Cancer Res. 1997. PMID: 9815555 Clinical Trial.

7

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Goldberg RM, et al. Among authors: erlichman c. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2363-70. Clin Cancer Res. 1997. PMID: 9815635 Clinical Trial.

8

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. Pitot HC, et al. Among authors: erlichman c. Clin Cancer Res. 1999 Mar;5(3):525-31. Clin Cancer Res. 1999. PMID: 10100703 Clinical Trial.

9

Optimum doses of irinotecan.

Erlichman C, Goldberg RM, Pitot HC, O'Connell MJ. Erlichman C, et al. Lancet. 1999 Apr 10;353(9160):1275-6. doi: 10.1016/s0140-6736(05)75197-7. Lancet. 1999. PMID: 10217115 No abstract available.

10

A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.

Adjei AA, Erlichman C. Adjei AA, et al. Among authors: erlichman c. Semin Oncol. 1999 Apr;26(2 Suppl 6):94-8. Semin Oncol. 1999. PMID: 10598562 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters